Diagnostic and treatment recommendations on perianal Crohn's disease

被引:0
作者
Mendoza, JL
Taxonera, C
Lana, R
Alba, C
García-Paredes, J
Díaz-Rubio, M
机构
[1] Hosp Clin San Carlos, Dept Gastroenterol, Inflammatory Bowel Dis Unit, Madrid, Spain
[2] Hosp Clin San Carlos, Dept Emergency Care, Madrid, Spain
关键词
Crohn's disease; perianal disease; diagnostic; treatment;
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Treatment of perianal fistulas in Crohn's disease should be defined on an individual basis. A combined medical and surgical approach is the optimal treatment. Adequate management of perianal fistula disease is based on the presence or absence of active proctitis, anatomic location, and fistula type. Furthermore, the presence of perianal abscesses must be ruled out. This evaluation includes digital rectal examination, endoscopy, and examination under anesthesia combined with pelvic magnetic resonance imaging or anorectal endoscopy ultrasonography findings.
引用
收藏
页码:46 / 56
页数:11
相关论文
共 29 条
[1]   Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease [J].
Baert, F ;
Noman, M ;
Vermeire, S ;
Van Assche, G ;
D'Haens, G ;
Carbonez, A ;
Rutgeerts, P .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (07) :601-608
[2]   Prognostic value of magnetic resonance imaging in the management of fistula-in-ano [J].
Chapple, KS ;
Spencer, JA ;
Windsor, ACJ ;
Wilson, D ;
Ward, J ;
Ambrose, NS .
DISEASES OF THE COLON & RECTUM, 2000, 43 (04) :511-516
[3]   The safety profile of infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients [J].
Colombel, JF ;
Loftus, EV ;
Tremaine, WJ ;
Egan, LJ ;
Harmsen, WS ;
Schleck, CD ;
Zinsmeister, AR ;
Sandborn, WJ .
GASTROENTEROLOGY, 2004, 126 (01) :19-31
[4]  
de Oca J, 2003, REV ESP ENFERM DIG, V95, P465
[5]   Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease [J].
Dejaco, C ;
Harrer, M ;
Waldhoer, T ;
Miehsler, W ;
Vogelsang, H ;
Reinisch, W .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 18 (11-12) :1113-1120
[6]   Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trial [J].
Farrell, RJ ;
Alsahli, M ;
Jeen, YT ;
Falchuk, KR ;
Peppercorn, MA ;
Michetti, P .
GASTROENTEROLOGY, 2003, 124 (04) :917-924
[7]   A new system for grading recommendations in evidence based guidelines [J].
Harbour, R ;
Miller, J .
BRITISH MEDICAL JOURNAL, 2001, 323 (7308) :334-336
[8]   CLINICAL CLASSIFICATION OF PERIANAL CROHNS-DISEASE [J].
HUGHES, LE .
DISEASES OF THE COLON & RECTUM, 1992, 35 (10) :928-932
[9]   Tuberculosis associated with infliximab, a tumor necrosis factor (alpha)-neutralizing agent [J].
Keane, J ;
Gershon, S ;
Wise, RP ;
Mirabile-Levens, E ;
Kasznica, J ;
Schwieterman, WD ;
Siegel, JN ;
Braun, MM .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (15) :1098-1104
[10]   Predictive factors of response of perianal Crohn's disease to azathioprine or 6-mercaptopurine [J].
Lecomte, T ;
Contou, JF ;
Beaugerie, L ;
Carbonnel, F ;
Cattan, S ;
Gendre, JP ;
Cosnes, J .
DISEASES OF THE COLON & RECTUM, 2003, 46 (11) :1469-1475